Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
Crossref DOI link: https://doi.org/10.1007/s11060-015-1795-0
Published Online: 2015-05-03
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nagpal, Seema
Recht, Cathy Kahn
Bertrand, Sophie
Thomas, Reena Parada
Ajlan, Abdulrazag
Pena, Justine
Gershon, Megan
Coffey, Gwen
Kunz, Pamela L.
Li, Gordon
Recht, Lawrence D.
License valid from 2015-05-03